-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).
-
Summary
-
U.S. Stem Cell, Inc. quarterly/annual Revenues history and growth rate from Q1 2017 to Q4 2022.
- U.S. Stem Cell, Inc. Revenues for the quarter ending December 31, 2022 was $20K, a 15.3% decline year-over-year.
- U.S. Stem Cell, Inc. Revenues for the twelve months ending December 31, 2022 was $82K, a 59.1% decline year-over-year.
- U.S. Stem Cell, Inc. annual Revenues for 2022 was $82K, a 59.1% decline from 2021.
- U.S. Stem Cell, Inc. annual Revenues for 2021 was $201K, a 27.6% decline from 2020.
- U.S. Stem Cell, Inc. annual Revenues for 2020 was $277K, a 91% decline from 2019.
Revenues, Trailing 12 Months (USD)
Revenues, Quarterly (USD)
Revenues, YoY Quarterly Growth (%)